An investigational antibody-drug conjugate proved active and safe for patients with previously treated HER2-mutant non-small ...

Surgeons can remove tissue in your tumor (called a biopsy) to test your breast tumor for a PIK3CA mutation, or in some cases, a blood test can find the defect. The HER2 gene makes a protein called ...

Boehringer's zongertinib and Bayer's BAY 2927088 are in phase 3 testing for advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations, and the WCLC congress gave an opportunity to ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

The phase 1b BEAMION LUNG-1 trial reported a 71% objective response rate and favorable safety profile for zongertinib. HER2 mutations in NSCLC are linked to poor prognosis, affecting 2%-4% of cases, ...

Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression 40% compared to standard treatment for an ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

If approved, trastuzumab rezetecan could provide a new option for the small percentage of patients whose tumors harbor HER2 mutations. An investigational antibody-drug conjugate proved active and ...